Roche

Roche advances the Africa Breast Cancer Ambition to power economic growth and transform healthcare across Africa

As global leaders gather for Unstoppable Africa 2026, Roche (www.Roche.com) has reaffirmed its commitment to advancing healthcare as a primary driver of economic resilience across the continent.

<a href="https://www.fiercebiotech.com/biotech/roches-phase-3-win-tees-fight-novartis-blockbuster-kidney-disease-market" hreflang="en">Roche’s phase 3 win tees up fight with Novartis for blockbuster kidney disease market</a>

Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis-partnered, would-be blockbuster candidate.

Sep 23, 2026 · byFierce Biotech

Roche proposes former Takeda CEO for board seat

STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates

Sep 22, 2026 · bySTAT

<a href="https://www.fiercebiotech.com/biotech/roches-glp-1gip-drug-hits-phase-2-diabetes-trial-fueling-best-disease-prediction" hreflang="en">Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes</a>

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with Type 2 diabetes and overweight or obesity.

Sep 22, 2026 · byFierce Biotech

STAT+: Roche expands its Boston footprint with new research center

A gene therapy approved for Sanfilippo syndrome, good and bad news for Xenon Pharma, and more biotech news

Sep 18, 2026 · bySTAT

<a href="https://www.fiercepharma.com/pharma/roche-lunsumio-delivers-positive-confirmatory-trial-readout-follicular-lymphoma" hreflang="en">Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma</a>

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary endpoint in earlier-line follicular lymphoma.

Sep 17, 2026 · byFierce Pharma

<a href="https://www.fiercebiotech.com/biotech/roche-pays-dualitas-365m-pair-big-bispecific-screening-drive" hreflang="en">Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive</a>

Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.

Sep 17, 2026 · byFierce Biotech

<a href="https://www.fiercebiotech.com/biotech/roche-and-medilink-notch-phase-3-lung-cancer-win-trail-gsk-cross-trial-survival" hreflang="en">Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival</a>

MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survival fell short of the bar set by GSK’s rival asset.

Sep 14, 2026 · byFierce Biotech

Roche advances first AI drug discovery project with Recursion Pharmaceuticals

AI-driven drug discovery could revolutionize treatment approaches, offering new hope for complex diseases and reshaping pharmaceutical R&D. The post Roche advances first AI drug discovery project with Recursion Pharmaceuticals appeared first on Crypto Briefing .

Aug 5, 2026 · byCryptoBriefing